Cancer remains a critical health concern, impacting patients, families, communities, and healthcare systems. While innovative treatments have enhanced survival and have reduced symptoms, perceptions of the value of such innovation differ among stakeholders. Patients value both the quality and duration of life when considering treatments, while clinicians, regulators, and payers also highly value these factors, in addition to their commitment to ensure the efficacy and safety of therapies.

Although Overall Survival (OS) continues to be vital for oncology decision-making, it is important to consider additional oncology-relevant endpoints, including patient-reported outcomes (PROs), to enhance patient outcomes and to optimise healthcare resource use. Such endpoints are increasingly incorporated in clinical trials for assessing new cancer treatments' benefits, yet acceptance and usage in reimbursement decisions across Europe pose challenges.

How can we overcome these obstacles and ensure that oncology-relevant endpoints reflect the value of innovation for patients, clinicians, payers and society?

Organised by EFPIA, this virtual event presented the findings of a multistakeholder thought piece that explores these questions and proposes actions for different stakeholder groups to improve the understanding, acceptance and use of oncology-relevant endpoints in oncology reimbursement decision-making.

A panel of experts from payers, clinicians, patient advocacy groups and industry shared and discussed their perspectives.

SPEAKERS DISCUSSED

• The value of looking at oncology-relevant endpoints beyond OS and PROs in reimbursement decision-making
• The main barriers to the acceptance and use of oncology-relevant endpoints beyond OS in reimbursement decision-making
• Proposed actions to drive adoption of oncology-relevant endpoints beyond OS in reimbursement decision-making

WATCH THE EVENT RECORDING